Cargando…
Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model
Hepatocellular carcinoma (HCC) is the 2(nd) leading cause of cancer-related deaths every year globally. The most common form of treatment, hepatic arterial infusion (HAI), involves the direct injection of doxorubicin (DOX) into the hepatic artery. It is plagued with limited therapeutic efficacy and...
Autores principales: | Kuruvilla, Sibu P., Tiruchinapally, Gopinath, Crouch, A. Colleen, ElSayed, Mohamed E. H., Greve, Joan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567696/ https://www.ncbi.nlm.nih.gov/pubmed/28829785 http://dx.doi.org/10.1371/journal.pone.0181944 |
Ejemplares similares
-
Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery
por: Lee, Sang Joon, et al.
Publicado: (2015) -
INKing the Cardiotoxicity Out of Doxorubicin
por: Guo, Zhen, et al.
Publicado: (2023) -
Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity
por: Rephaeli, A, et al.
Publicado: (2007) -
Role of acetylation in doxorubicin-induced cardiotoxicity
por: Li, Daisong, et al.
Publicado: (2021) -
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity
por: Alyasiry, Esraa, et al.
Publicado: (2022)